Status:
COMPLETED
Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborating Sponsors:
Universidad del Valle, Guatemala
University of Alabama at Birmingham
Conditions:
Onchocerciasis
Eligibility:
All Genders
5+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether rifampin and/or azithromycin are effective in the treatment of river blindness (onchocerciasis).
Detailed Description
Mass treatment with ivermectin (Mectizan, Merck \& Co) is the mainstay of the current efforts to control onchocerciasis, but the drug is not lethal to adult Onchocerca volvulus parasites. Wolbachia, a...
Eligibility Criteria
Inclusion
- Males and non-pregnant/non lactating females \>5 years of age
- One onchocercal nodule in an anatomical position where it can be easily removed surgically
Exclusion
- Pregnancy (based on urine pregnancy test)
- Breast-feeding
- Women taking oral contraceptives
- Allergy or other adverse reaction to either medication
- Use of other medications that might interact with rifampin
- Clinical evidence of liver disease (jaundice, swollen abdomen)
- Clinical evidence of chronic disease/alcoholism
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
End Date :
May 1 2004
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00127504
Start Date
July 1 2003
End Date
May 1 2004
Last Update
August 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universidad del Valle/MERTU
Guatemala City, Guatemala